Outsmarting a Clever One
Update: 2025-07-30
Description
Despite the successes of immunotherapies to date, about 75 to 80 percent of cancer patients don’t respond to current immunotherapy treatments. Faron Pharmaceuticals is hoping to help change that with its experimental therapy bexmarilimab, which is in development to treat myelodysplastic syndrome. Bexmarilimab targets CLEVER-1, a checkpoint inhibitor found on macrophages, a type of myeloid cell that plays an essential role in the immune system. We spoke to Juho Jalkanen, founder and CEO of Faron, about how the tumor microenvironment can suppress macrophages, how the company’s macrophage checkpoint inhibitor works, and the challenges a Finland-based company faces accessing the capital markets.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
